MENLO PARK, Calif., Oct. 25, 2012 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq:PACB) today announced financial results for the third quarter ended September 30, 2012.
During the third quarter of 2012, the Company recognized revenue from SMRT® Cell and reagent consumables, instrument service contracts and grants. Revenue for the third quarter of 2012 totaled $2.8 million compared to revenue of $7.3 million for the second quarter of 2012. Net loss for the quarter was $22.7 million compared to the $22.5 million net loss during the second quarter of 2012.
